| Ark Therapeutics wins approval to initiate Phase III renal disease study (Pharmaceutical Business Review) |
|
|
UK-based Ark Therapeutics Group has completed the work requested by the FDA to qualify a potency test for Trinam. As a result, the company has now been notified by the FDA that it can commence patient recruitment into its Trinam Phase III trial. |